| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,570,000 |
| Market
Cap: |
36.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.54 - $15.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$0 |
$49,985 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
900 |
40,606 |
81,659 |
2,116,402 |
| Total Sell Value |
$5,181 |
$176,009 |
$209,415 |
$2,250,236 |
| Total People Sold |
2 |
6 |
7 |
8 |
| Total Sell Transactions |
3 |
12 |
22 |
61 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paulson Richard A. |
President and CEO |
• • – |
2025-05-06 |
4 |
S |
$7.12 |
$1,680 |
D/D |
(236) |
82,503 |
|
30% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2025-04-23 |
4 |
S |
$6.17 |
$2,585 |
D/D |
(419) |
28,853 |
|
30% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-04-04 |
4 |
S |
$3.74 |
$916 |
D/D |
(245) |
82,739 |
|
-14% |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2025-03-04 |
4 |
S |
$6.29 |
$17,568 |
D/D |
(2,793) |
21,047 |
|
31% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2025-03-04 |
4 |
S |
$6.29 |
$21,669 |
D/D |
(3,445) |
34,314 |
|
31% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2025-03-04 |
4 |
S |
$6.29 |
$22,562 |
D/D |
(3,587) |
29,272 |
|
31% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-03-04 |
4 |
S |
$6.29 |
$73,555 |
D/D |
(11,694) |
82,984 |
|
31% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-03-04 |
4 |
S |
$6.29 |
$22,317 |
D/D |
(3,548) |
27,414 |
|
31% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-03-04 |
4 |
S |
$6.29 |
$3,592 |
D/D |
(571) |
9,713 |
|
31% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
94,678 |
|
- |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
933 |
10,284 |
|
- |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,999 |
32,859 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,583 |
23,840 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,999 |
37,759 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,583 |
30,962 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-02-18 |
4 |
S |
$0.63 |
$3,726 |
D/D |
(5,914) |
320,714 |
|
54% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-02-04 |
4 |
S |
$0.65 |
$2,664 |
D/D |
(4,099) |
1,120,158 |
|
53% |
|
| Macomber Lori |
EVP, CFO & Treasurer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
160,000 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-01-06 |
4 |
S |
$0.78 |
$3,175 |
D/D |
(4,055) |
1,124,257 |
|
57% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-12-04 |
4 |
S |
$0.81 |
$2,932 |
D/D |
(3,620) |
1,128,312 |
|
63% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2024-11-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
140,300 |
|
-54% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-11-05 |
4 |
S |
$0.91 |
$3,346 |
D/D |
(3,675) |
1,131,932 |
|
54% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-10-04 |
4 |
S |
$0.88 |
$3,172 |
D/D |
(3,607) |
1,135,607 |
|
31% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2024-09-04 |
4 |
S |
$0.72 |
$5,089 |
D/D |
(7,050) |
391,054 |
|
11% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2024-09-04 |
4 |
S |
$0.72 |
$3,866 |
D/D |
(5,356) |
404,051 |
|
11% |
|
563 Records found
|
|
Page 1 of 23 |
|
|
0.08 (1.82%) 
